All In Biotech

Drug Trial Radar · NCT04936178

A Study of NB003 in Patients With Advanced Malignancies

A Multicenter Phase 1, Open-Label Study of NB003 to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

258

Actual

Start

Aug 6, 2021

Primary completion

Aug 1, 2025

Study completion Aug 1, 2025

Sponsor

Sponsor type
Industry
First posted
Jun 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This a A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB003 in Subjects with Advanced Malignancies

Conditions

  • Advanced Solid Tumor

Interventions

  • NB003 tabletsDrug

    NB003 tablets will be administered at assigned doses for escalation phase and RP2D doses for expansion phase orally twice daily for repeated 28-day cycles until discontinuation criteria are met.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicitiesTime frame: Approximately 24 months since the escalation first subject enrolled
  2. Incidence of adverse eventsTime frame: Approximately 24 months since the escalation first subject enrolled; Approximately 26 months since the Expansion first subject enrolled
  3. Objective Response Rate (ORR)Time frame: Approximately 26 months since the Expansion first subject enrolled
  4. Duration of Response(DOR)Time frame: Approximately 26 months since the Expansion first subject enrolled.

Locations

32 sites in 6 countries. Site status is shown where the registry gives one.

  • Standford University

    Stanford, California

  • Mayo Clinic

    Jacksonville, Florida

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Memorial Sloan Kettering Cancer Center

    Long Island City, New York

  • Oregon Health & Science University (OHSU)

    Portland, Oregon

  • U T MD Anderson Cancer Center Investigational Pharmacy Services

    Houston, Texas

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guandong, China

  • The First Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guandong, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Xiangya Hospital, Central South University

    Changsha, Huanan, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • The Affiliated Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China

  • Liaoning Cancer Hospital & Institute

    Shenyang, Liaoning, China

  • The Second Affiliated Hospital of Xi'An Jiaotong University

    Xi'an, Shaanxi, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • Renji Hospital Shanghai Jiaotong University School of Medicine - West Branch

    Shanghai, Shanghai Municipality, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital of Zhejiang University school of medicine

    Hangzhou, Zhejiang, China

  • Centre Léon Bérard

    Lyon, Rhone, France

  • Institut Gustave Roussy

    Villejuif, Val de Marne, France

  • Asan Medical Center

    Seoul, Seoul, South Korea

  • Samsung Medical Center

    Seoul, Seoul, South Korea

  • Hospital Universitari Vall d'Hebron

    Barcelona, Barcelona, Spain

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, Madrid, Spain

  • Royal Marsden Hospital-London

    London, London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.